Related references
Note: Only part of the references are listed.Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
Rakesh K. Jain
CANCER CELL (2014)
Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial
Edward B. Garon et al.
LANCET (2014)
Nab-Paclitaxel Is an Active Drug in Preclinical Model of Pediatric Solid Tumors
Libo Zhang et al.
CLINICAL CANCER RESEARCH (2013)
A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer
Andrew X. Zhu et al.
CLINICAL CANCER RESEARCH (2013)
PointBreak: A Randomized Phase III Study of Pemetrexed Plus Carboplatin and Bevacizumab Followed by Maintenance Pemetrexed and Bevacizumab Versus Paclitaxel Plus Carboplatin and Bevacizumab Followed by Maintenance Bevacizumab in Patients With Stage IIIB or IV Nonsquamous Non-Small-Cell Lung Cancer
Jyoti D. Patel et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Normalizing Tumor Microenvironment to Treat Cancer: Bench to Bedside to Biomarkers
Rakesh K. Jain
JOURNAL OF CLINICAL ONCOLOGY (2013)
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation
Tracy T. Batchelor et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis
Jun Cai et al.
WORLD JOURNAL OF SURGICAL ONCOLOGY (2013)
Rapid Decrease in Delivery of Chemotherapy to Tumors after Anti-VEGF Therapy: Implications for Scheduling of Anti-Angiogenic Drugs
Astrid A. M. Van der Veldt et al.
CANCER CELL (2012)
Weekly nab-Paclitaxel in Combination With Carboplatin Versus Solvent-Based Paclitaxel Plus Carboplatin as First-Line Therapy in Patients With Advanced Non-Small-Cell Lung Cancer: Final Results of a Phase III Trial
Mark A. Socinski et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner
Vikash P. Chauhan et al.
NATURE NANOTECHNOLOGY (2012)
Effects of Sorafenib on Intra-Tumoral Interstitial Fluid Pressure and Circulating Biomarkers in Patients with Refractory Sarcomas (NCI Protocol 6948)
Chandrajit P. Raut et al.
PLOS ONE (2012)
Phase I Study of Cetuximab, Irinotecan, and Vandetanib (ZD6474) as Therapy for Patients with Previously Treated Metastastic Colorectal Cancer
Jeffrey A. Meyerhardt et al.
PLOS ONE (2012)
Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
Yuhui Huang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2012)
Implementing multiplexed genotyping of non-small-cell lung cancers into routine clinical practice
L. V. Sequist et al.
ANNALS OF ONCOLOGY (2011)
PHASE II STUDY OF NEOADJUVANT BEVACIZUMAB AND RADIOTHERAPY FOR RESECTABLE SOFT TISSUE SARCOMAS
Sam S. Yoon et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2011)
Molecular mechanisms and clinical applications of angiogenesis
Peter Carmeliet et al.
NATURE (2011)
NORMALIZATION OF THE VASCULATURE FOR TREATMENT OF CANCER AND OTHER DISEASES
Shom Goel et al.
PHYSIOLOGICAL REVIEWS (2011)
Overall survival with cisplatin-gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
M. Reck et al.
ANNALS OF ONCOLOGY (2010)
Clinical Course of Advanced Non-Small-Cell Lung Cancer Patients Experiencing Hypertension During Treatment With Bevacizumab in Combination With Carboplatin and Paclitaxel on ECOG 4599
Suzanne E. Dahlberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Phase II Study of Cediranib, an Oral Pan-Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent Glioblastoma
Tracy T. Batchelor et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Efficacy, Safety, and Potential Biomarkers of Sunitinib Monotherapy in Advanced Hepatocellular Carcinoma: A Phase II Study
Andrew X. Zhu et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer
Craig Reynolds et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Biomarkers of response and resistance to antiangiogenic therapy
Rakesh K. Jain et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100
Bryan P. Schneider et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer
Alan Sandler et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
False discovery control with p-value weighting
Christopher R. Genovese et al.
BIOMETRIKA (2006)
Normalization of tumor vasculature: An emerging concept in antiangiogenic therapy
RK Jain
SCIENCE (2005)
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
CG Willett et al.
NATURE MEDICINE (2004)
New guidelines to evaluate the response to treatment in solid tumors
F Duffaud et al.
BULLETIN DU CANCER (2000)
New guidelines to evaluate the response to treatment in solid Tumors
P Therasse et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2000)
Share Paper
